| 引用本文: | 郑成,赵维良,依泽,曹晖,蔡少青.中国药典2020年版中药材基原问题探究[J].中国现代应用药学,2021,38(20):2512-2517. |
| ZHENG Cheng,ZHAO Weiliang,YI Ze,CAO Hui,CAI Shaoqing.Textual Research on the Origins of Chinese Medicinal Materials in Chinese Pharmacopoeia 2020 Edition[J].Chin J Mod Appl Pharm(中国现代应用药学),2021,38(20):2512-2517. |
|
| 本文已被：浏览 1794次 下载 2351次 |
码上扫一扫！ |
|
|
| 中国药典2020年版中药材基原问题探究 |
|
郑成1, 赵维良1,2, 依泽1, 曹晖3, 蔡少青4
|
|
1.浙江省食品药品检验研究院, 国家药品监督管理局中成药质量评价重点实验室, 杭州 310052;2.杭州师范大学药学院, 杭州 311121;3.暨南大学药学院, 广州 510632;4.北京大学药学院, 北京 100083
|
|
| 摘要: |
| 目的 查找中国药典2020年版中药材基原存在的问题，为完善修订中国药典药材基原内容奠定基础。方法 针对所有中国药典2020年版一部药材标准和四部附录基原内容，查询《中国植物志》（中英文版）、《中国动物志》等权威著作，中国自然标本馆等专题数据库和相关研究文献，对发现的问题进行考证或药材商品考察研究。结果 中国药典2020年版一部和四部附录中，存在中药材基原物种问题的品种共计10个，药材基原拉丁学名问题4个，药材基原中文名称问题3个；另基原有争议的品种3个。结论 经研究考订，中国药典2020年版上述涉及基原物种、拉丁学名和中文名称问题的共计17个品种均需修订完善，并提出了初步的修改建议；另外3个品种基原虽有争议，但认为不需修改。 |
| 关键词: 中国药典 基原考证 基原物种 |
| DOI：10.13748/j.cnki.issn1007-7693.2021.20.006 |
| 分类号:R282 |
| 基金项目:浙江省食品药品安全"十三五"规划-中药材数字化标本馆（浙食药Z-2016001）；浙江省食品药品监管系统科技计划项目（2019010） |
|
| Textual Research on the Origins of Chinese Medicinal Materials in Chinese Pharmacopoeia 2020 Edition |
|
ZHENG Cheng1, ZHAO Weiliang1,2, YI Ze1, CAO Hui3, CAI Shaoqing4
|
|
1.Zhejiang Institute for Food and Drug Control, NMPA Key Laboratory for Quality Evaluation of Traditional Chinese Medicine, Hangzhou 310052, China;2.College of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China;3.College of Pharmacy, Jinan University, Guangzhou 510632, China;4.College of Pharmacy, Beijing University, Beijing 100083, China
|
| Abstract: |
| OBJECTIVE To discover the problems of origins to Chinese medicinal materials in Chinese Pharmacopoeia 2020 Edition(ChP 2020), and to lay a foundation for improving and revising the contents in origins of Chinese Pharmacopoeia. METHODS For all the origins in ChP 2020(Volume Ⅰ and Volume Ⅳ Appendix) consult authoritative works such as Flora of China(Chinese and English version), Fauna of China, Chinese Field Herbarium special databases and relevant research literatures. Conduct textual research or commodity investigation on the problems found. RESULTS There were 10 species with the problems of Chinese medicinal materials origins, 4 species with the problems of Latin scientific names and 3 species with the problems of the Chinese names, and also there were 3 species with the original controversy in ChP 2020(Volume Ⅰ and Volume Ⅳ Appendix). CONCLUSION Through research and textualization, the above-mentioned 17 species involving the problems of species of origins, Latin scientific names and Chinese names in ChP 2020 all need to be revised and improved. And put forward the preliminary modification suggestion. The other three species don't need to be modified although their species of origins are controversial. |
| Key words: Chinese Pharmacopoeia textual research on origins species of origins |
